Abstract
BACKGROUND: Hypertensive disorders of pregnancy are a major contributor to death and disability for pregnant women and their infants. The diagnosis of preeclampsia by using blood pressure and proteinuria is of limited use because they are tertiary, downstream features of the disease. Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated placental dysfunction in preeclampsia, with known low plasma concentrations in the disease. METHODS AND RESULTS: In a prospective multicenter study, we studied the diagnostic accuracy of low plasma PlGF concentration (
Original language | English |
---|---|
Pages (from-to) | 2121-31 |
Number of pages | 2089 |
Journal | Circulation |
Volume | 128 |
Issue number | 19 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- Adult
- Biological Markers/blood
- Chemistry, Clinical/*standards
- Female
- Follow-Up Studies
- Humans
- Pre-Eclampsia/*blood/*diagnosis/epidemiology
- Predictive Value of Tests
- Pregnancy
- Pregnancy Proteins/*blood
- Prospective Studies
- Reproducibility of Results
- Risk Factors
- Sensitivity and Specificity
Fingerprint
Dive into the research topics of 'Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study'. Together they form a unique fingerprint.Impacts
-
Placenta growth factor (PlGF) blood test for pre-eclampsia recommended by NICE then rolled out more widely by NHS England speeding up diagnosis and helping determine those most at risk
Myers, J. (Corresponding participant), Ormesher, L. (Participant), Johnstone, E. (Participant) & Duhig, K. (Participant)
Impact: Health and wellbeing, Economic